Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 374

1.

Advances in immune checkpoint inhibitors for bone sarcoma therapy.

Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z.

J Bone Oncol. 2019 Jan 29;15:100221. doi: 10.1016/j.jbo.2019.100221. eCollection 2019 Apr. Review.

2.

Low dose radiotherapy is associated with local complications but not disease control in sacral chordoma.

Houdek MT, Rose PS, Hevesi M, Schwab JH, Griffin AM, Healey JH, Petersen IA, DeLaney TF, Chung PW, Yaszemski MJ, Wunder JS, Hornicek FJ, Boland PJ, Sim FH, Ferguson PC; Other Members of the Sacral Tumor Society.

J Surg Oncol. 2019 Feb 7. doi: 10.1002/jso.25399. [Epub ahead of print]

PMID:
30734292
3.

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.

Wang J, Dean DC, Hornicek FJ, Shi H, Duan Z.

FASEB J. 2019 Feb 6:fj201801789RR. doi: 10.1096/fj.201801789RR. [Epub ahead of print]

PMID:
30726104
4.

Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.

Tang F, Min L, Seebacher NA, Li X, Zhou Y, Hornicek FJ, Wei Y, Tu C, Duan Z.

J Orthop Res. 2019 Jan 22. doi: 10.1002/jor.24227. [Epub ahead of print]

PMID:
30667081
5.

Small-molecule targeting of brachyury transcription factor addiction in chordoma.

Sharifnia T, Wawer MJ, Chen T, Huang QY, Weir BA, Sizemore A, Lawlor MA, Goodale A, Cowley GS, Vazquez F, Ott CJ, Francis JM, Sassi S, Cogswell P, Sheppard HE, Zhang T, Gray NS, Clarke PA, Blagg J, Workman P, Sommer J, Hornicek F, Root DE, Hahn WC, Bradner JE, Wong KK, Clemons PA, Lin CY, Kotz JD, Schreiber SL.

Nat Med. 2019 Feb;25(2):292-300. doi: 10.1038/s41591-018-0312-3. Epub 2019 Jan 21.

PMID:
30664779
6.

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.

Ma H, Seebacher NA, Hornicek FJ, Duan Z.

EBioMedicine. 2019 Jan;39:182-193. doi: 10.1016/j.ebiom.2018.12.022. Epub 2018 Dec 20.

7.

Is malnutrition associated with postoperative complications in patients with primary bone sarcomas?

Park A, Lans J, Raskin K, Hornicek F, Schwab J, Lozano Calderon S.

J Surg Oncol. 2019 Mar;119(3):324-328. doi: 10.1002/jso.25332. Epub 2018 Dec 16.

PMID:
30554419
8.

Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.

Li X, Seebacher NA, Xiao T, Hornicek FJ, Duan Z.

J Orthop Res. 2019 Feb;37(2):510-521. doi: 10.1002/jor.24189. Epub 2019 Jan 3.

PMID:
30488489
9.

Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution.

van Wulfften Palthe ODR, Tromp I, Ferreira A, Fiore A, Bramer JAM, van Dijk NC, DeLaney TF, Schwab JH, Hornicek FJ.

Spine J. 2018 Nov 14. pii: S1529-9430(18)31206-3. doi: 10.1016/j.spinee.2018.11.002. [Epub ahead of print]

PMID:
30445184
10.

RNA sequencing (RNA-Seq) and its application in ovarian cancer.

Wang J, Dean DC, Hornicek FJ, Shi H, Duan Z.

Gynecol Oncol. 2019 Jan;152(1):194-201. doi: 10.1016/j.ygyno.2018.10.002. Epub 2018 Oct 5. Review.

PMID:
30297273
11.

Application of liquid biopsy in bone and soft tissue sarcomas: Present and future.

Li X, Seebacher NA, Hornicek FJ, Xiao T, Duan Z.

Cancer Lett. 2018 Dec 28;439:66-77. doi: 10.1016/j.canlet.2018.09.012. Epub 2018 Sep 14.

PMID:
30223067
12.

High Risk of Venous Thromboembolism After Surgery for Long Bone Metastases: A Retrospective Study of 682 Patients.

Groot OQ, Ogink PT, Janssen SJ, Paulino Pereira NR, Lozano-Calderon S, Raskin K, Hornicek F, Schwab JH.

Clin Orthop Relat Res. 2018 Oct;476(10):2052-2061. doi: 10.1097/CORR.0000000000000463.

PMID:
30179923
13.

From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma.

Dean DC, Shen S, Hornicek FJ, Duan Z.

Cancer Metastasis Rev. 2018 Dec;37(4):719-731. doi: 10.1007/s10555-018-9763-8. Review.

PMID:
30167827
14.

Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors.

Sanford NN, Miao R, Wang H, Goldberg S, Jacobson A, Brunner AM, Cote GM, Yock TI, Ebb DH, Chen YB, Jee KW, Hornicek F, DeLaney TF, Choy E, Chen YL.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):52-61. doi: 10.1016/j.ijrobp.2018.08.037. Epub 2018 Aug 28.

PMID:
30165126
15.

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.

Liao Y, Sassi S, Halvorsen S, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

Sci Rep. 2018 Aug 9;8(1):12107. doi: 10.1038/s41598-018-30644-x.

16.

A Phase 1 Study of Nilotinib Plus Radiation in High-Risk Chordoma.

Cote GM, Barysauskas CM, DeLaney TF, Schwab J, Raskin K, Lozano-Calderon S, Bernstein K, Mullen JT, Haynes AB, Hornicek F, Chen YE, Choy E.

Int J Radiat Oncol Biol Phys. 2018 Aug 3. pii: S0360-3016(18)33471-0. doi: 10.1016/j.ijrobp.2018.07.2013. [Epub ahead of print]

PMID:
30077789
17.

Henry J. Mankin: A Trailblazer in Skeletal Pathology Research.

Sun CM, Schwab JH, Hornicek FJ.

Spine (Phila Pa 1976). 2018 Jun 8. doi: 10.1097/BRS.0000000000002730. [Epub ahead of print]

PMID:
29889796
18.

Complications and reoperations after surgery for 647 patients with spine metastatic disease.

Paulino Pereira NR, Ogink PT, Groot OQ, Ferrone ML, Hornicek FJ, van Dijk CN, Bramer JAM, Schwab JH.

Spine J. 2019 Jan;19(1):144-156. doi: 10.1016/j.spinee.2018.05.037. Epub 2018 Jun 1.

PMID:
29864546
19.

Lower Extremity Megaprostheses in Orthopaedic Oncology.

Lozano Calderón SA, Kuechle J, Raskin KA, Hornicek FJ.

J Am Acad Orthop Surg. 2018 Jun 15;26(12):e249-e257. doi: 10.5435/JAAOS-D-16-00218.

PMID:
29781818
20.

Functional Outcomes and Complications After Oncologic Reconstruction of the Proximal Humerus.

Nota S, Teunis T, Kortlever J, Ferrone M, Ready J, Gebhardt M, Raskin K, Hornicek F, Schwab J, Lozano Calderon S.

J Am Acad Orthop Surg. 2018 Jun 1;26(11):403-409. doi: 10.5435/JAAOS-D-16-00551.

PMID:
29762195

Supplemental Content

Loading ...
Support Center